From blockbuster medicine to personalized medicine

Personalized Medicine

Volumn 5, Issue 1, 2008, Pages 55-63

  Jørgensen, Jan Trøst ^a  

^a AGILENT TECHNOLOGIES   (United States)

Author keywords

Blockbuster medicine; Cancer; CYP; HER2; Infividualized therapy; Personalized medicine; Pharmacodiagnostic test; Predictive biomarkers; Stratified medicine; TOP2A

Indexed keywords

ANASTROZOLE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPECITABINE; CETUXIMAB; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESFLURANE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; IRINOTECAN; LAPATINIB; LETROZOLE; LIDOCAINE; MELANOCORTIN 1 RECEPTOR; NEUROLEPTIC AGENT; PROTON PUMP INHIBITOR; TAMOXIFEN; TAMOXIFEN CITRATE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; UNINDEXED DRUG;

ARTICLE; BIOTECHNOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC TEST; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; INDIVIDUALIZATION; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PHARMACOGENETICS; PHILOSOPHY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 38049160820     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.1.55     Document Type: Article

References (23)

1. Sikora K: Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv. Cancer Res. 96, 345-369 (2007).
2. Woodcock J: The prospects for 'personalized medicine' in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
3. Whiteley P: The case for personalized medicine. Presented at: 14th Intemational Tri-Conference on Molecular Medicine. Abstract. Moscone convention center, San Francisco, CA, USA, February 27-March 2 (2007).
4. Jørgensen JT, Nielsen KV, Ejlertsen B: Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist 12, 397-405 (2007).
5. Morgan LR, Schein PS, Woolley PV et al.: Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat. Rep. 60, 1437-1443 (1976).
6. Heel RC, Brogden RN, Speight TM et al.: Tamoxifen: a review of Its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16, 1-24 (1978).
7. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77 (1998).
8. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med. 344, 783-792 (2001).
9. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 28(Suppl. 3), 13-19 (2001).
10. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J Med. 353, 1673-1684 (2005).
11. Piocart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
12. Knoop AS, Knudsen H, Balslev E et al.: Retrospective analysis of topoisomerase Ila (TOP2A) amplifications and deletions as predictive markers in primary breast cancer patients randomized to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J C1in. Oncol. 23, 7483-7490 (2005).
13. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
14. Jørgensen JT. Developing molecular diagnostics for cancer. Presented at: 14th International Tri-Conference on Molecular Medicine. Abstract. Moscone convention center, San Francisco, CA, USA, February 27-March 2 (2007).
15. Liem EB, Lin CM, Suleman MI et al.: Anesthetic requirement is increased in redheads. Anesthesiology l0l, 279-283 (2004).
16. Liem EB, Joiner TV, Tsueda K et al.: Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anethesiology 102, 509-514 (2005).
17. Frye RF: Probing the world of cytochromes p450 enzymes. Mol. Interv. 4, 157-162 (2005).
18. Lesko LJ: Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther. 81, 807-816 (2007).
19. Simon R, Maitournam, A: Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10, 6759-6763 (2004).
20. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin. Oncol. 31(Suppl. 3), 21-27 (2004).
21. Sikora K: Paying for cancer care - a new dilemma. J. R. Soc. Med. 100, 166-169 (2007).
22. Thisheim, MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev Drug Disrov. 6, 287-293 (2007).
23. Garrison LP, Austin MJF: Linking pharmacogenetic-based diagnostics and pharmaceuticals for personalized medicine: scientific and economic challenges. Health Affairs 25, 1281-1290 (2006).